Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis

By a wide margin, lung cancer is the most significant cause of cancer death in the United States and worldwide. The incidence of lung cancer increases with age, and Medicare beneficiaries are often at increased risk. Because of its demonstrated effectiveness in reducing mortality, lung cancer screen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American health & drug benefits 2014-08, Vol.7 (5), p.272-282
Hauptverfasser: Pyenson, Bruce S, Henschke, Claudia I, Yankelevitz, David F, Yip, Rowena, Dec, Ellynne
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 282
container_issue 5
container_start_page 272
container_title American health & drug benefits
container_volume 7
creator Pyenson, Bruce S
Henschke, Claudia I
Yankelevitz, David F
Yip, Rowena
Dec, Ellynne
description By a wide margin, lung cancer is the most significant cause of cancer death in the United States and worldwide. The incidence of lung cancer increases with age, and Medicare beneficiaries are often at increased risk. Because of its demonstrated effectiveness in reducing mortality, lung cancer screening with low-dose computed tomography (LDCT) imaging will be covered without cost-sharing starting January 1, 2015, by nongrandfathered commercial plans. Medicare is considering coverage for lung cancer screening. To estimate the cost and cost-effectiveness (ie, cost per life-year saved) of LDCT lung cancer screening of the Medicare population at high risk for lung cancer. Medicare costs, enrollment, and demographics were used for this study; they were derived from the 2012 Centers for Medicare & Medicaid Services (CMS) beneficiary files and were forecast to 2014 based on CMS and US Census Bureau projections. Standard life and health actuarial techniques were used to calculate the cost and cost-effectiveness of lung cancer screening. The cost, incidence rates, mortality rates, and other parameters chosen by the authors were taken from actual Medicare data, and the modeled screenings are consistent with Medicare processes and procedures. Approximately 4.9 million high-risk Medicare beneficiaries would meet criteria for lung cancer screening in 2014. Without screening, Medicare patients newly diagnosed with lung cancer have an average life expectancy of approximately 3 years. Based on our analysis, the average annual cost of LDCT lung cancer screening in Medicare is estimated to be $241 per person screened. LDCT screening for lung cancer in Medicare beneficiaries aged 55 to 80 years with a history of ≥30 pack-years of smoking and who had smoked within 15 years is low cost, at approximately $1 per member per month. This assumes that 50% of these patients were screened. Such screening is also highly cost-effective, at
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4163779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1563992822</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-b31e8e0e8693863fd134ca5b0aaca8b603df414a5e5089f9ef324efec4e4b1073</originalsourceid><addsrcrecordid>eNpVUE1LAzEQXUSxtfoXJEcvC9kkm914EKT4BYVe9LzMppM2mmZrslso_nlTrEUvb2bePN5j5iQbF0qwnKmKnh57yUbZRYzvlMqSVvQ8G7GS8UowPs6-5sZgsH5J3JBAg9cYSNQB0e_ZviMru1zlwcYPssaF1RCQtOjRWG0hWIwkwjahs3sEvyA2Et3FPsdkrftE3yaagO6HpAeXBnC7aONldmbARbw61En29vjwOn3OZ_Onl-n9LN8wKfu85QXWSLGWiteSm0XBhYaypQAa6lZSvjCiEFBiSWtlFBrOBKZogaItaMUn2d2P72Zo0wkafR_ANZtg1xB2TQe2-b_xdtUsu20jCsmrSiWDm4NB6D4HjH2ztlGjc-CxG2JTlJIrxWrGkvT6b9Yx5Pfj_BsYy4HD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1563992822</pqid></control><display><type>article</type><title>Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pyenson, Bruce S ; Henschke, Claudia I ; Yankelevitz, David F ; Yip, Rowena ; Dec, Ellynne</creator><creatorcontrib>Pyenson, Bruce S ; Henschke, Claudia I ; Yankelevitz, David F ; Yip, Rowena ; Dec, Ellynne</creatorcontrib><description>By a wide margin, lung cancer is the most significant cause of cancer death in the United States and worldwide. The incidence of lung cancer increases with age, and Medicare beneficiaries are often at increased risk. Because of its demonstrated effectiveness in reducing mortality, lung cancer screening with low-dose computed tomography (LDCT) imaging will be covered without cost-sharing starting January 1, 2015, by nongrandfathered commercial plans. Medicare is considering coverage for lung cancer screening. To estimate the cost and cost-effectiveness (ie, cost per life-year saved) of LDCT lung cancer screening of the Medicare population at high risk for lung cancer. Medicare costs, enrollment, and demographics were used for this study; they were derived from the 2012 Centers for Medicare &amp; Medicaid Services (CMS) beneficiary files and were forecast to 2014 based on CMS and US Census Bureau projections. Standard life and health actuarial techniques were used to calculate the cost and cost-effectiveness of lung cancer screening. The cost, incidence rates, mortality rates, and other parameters chosen by the authors were taken from actual Medicare data, and the modeled screenings are consistent with Medicare processes and procedures. Approximately 4.9 million high-risk Medicare beneficiaries would meet criteria for lung cancer screening in 2014. Without screening, Medicare patients newly diagnosed with lung cancer have an average life expectancy of approximately 3 years. Based on our analysis, the average annual cost of LDCT lung cancer screening in Medicare is estimated to be $241 per person screened. LDCT screening for lung cancer in Medicare beneficiaries aged 55 to 80 years with a history of ≥30 pack-years of smoking and who had smoked within 15 years is low cost, at approximately $1 per member per month. This assumes that 50% of these patients were screened. Such screening is also highly cost-effective, at &lt;$19,000 per life-year saved. If all eligible Medicare beneficiaries had been screened and treated consistently from age 55 years, approximately 358,134 additional individuals with current or past lung cancer would be alive in 2014. LDCT screening is a low-cost and cost-effective strategy that fits well within the standard Medicare benefit, including its claims payment and quality monitoring.</description><identifier>ISSN: 1942-2962</identifier><identifier>EISSN: 1942-2970</identifier><identifier>PMID: 25237423</identifier><language>eng</language><publisher>United States: Engage Healthcare Communications, LLC</publisher><subject>Regulatory</subject><ispartof>American health &amp; drug benefits, 2014-08, Vol.7 (5), p.272-282</ispartof><rights>Copyright © 2014 by Engage Healthcare Communications, LLC 2014 Engage Healthcare Communications, LLC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163779/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163779/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25237423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pyenson, Bruce S</creatorcontrib><creatorcontrib>Henschke, Claudia I</creatorcontrib><creatorcontrib>Yankelevitz, David F</creatorcontrib><creatorcontrib>Yip, Rowena</creatorcontrib><creatorcontrib>Dec, Ellynne</creatorcontrib><title>Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis</title><title>American health &amp; drug benefits</title><addtitle>Am Health Drug Benefits</addtitle><description>By a wide margin, lung cancer is the most significant cause of cancer death in the United States and worldwide. The incidence of lung cancer increases with age, and Medicare beneficiaries are often at increased risk. Because of its demonstrated effectiveness in reducing mortality, lung cancer screening with low-dose computed tomography (LDCT) imaging will be covered without cost-sharing starting January 1, 2015, by nongrandfathered commercial plans. Medicare is considering coverage for lung cancer screening. To estimate the cost and cost-effectiveness (ie, cost per life-year saved) of LDCT lung cancer screening of the Medicare population at high risk for lung cancer. Medicare costs, enrollment, and demographics were used for this study; they were derived from the 2012 Centers for Medicare &amp; Medicaid Services (CMS) beneficiary files and were forecast to 2014 based on CMS and US Census Bureau projections. Standard life and health actuarial techniques were used to calculate the cost and cost-effectiveness of lung cancer screening. The cost, incidence rates, mortality rates, and other parameters chosen by the authors were taken from actual Medicare data, and the modeled screenings are consistent with Medicare processes and procedures. Approximately 4.9 million high-risk Medicare beneficiaries would meet criteria for lung cancer screening in 2014. Without screening, Medicare patients newly diagnosed with lung cancer have an average life expectancy of approximately 3 years. Based on our analysis, the average annual cost of LDCT lung cancer screening in Medicare is estimated to be $241 per person screened. LDCT screening for lung cancer in Medicare beneficiaries aged 55 to 80 years with a history of ≥30 pack-years of smoking and who had smoked within 15 years is low cost, at approximately $1 per member per month. This assumes that 50% of these patients were screened. Such screening is also highly cost-effective, at &lt;$19,000 per life-year saved. If all eligible Medicare beneficiaries had been screened and treated consistently from age 55 years, approximately 358,134 additional individuals with current or past lung cancer would be alive in 2014. LDCT screening is a low-cost and cost-effective strategy that fits well within the standard Medicare benefit, including its claims payment and quality monitoring.</description><subject>Regulatory</subject><issn>1942-2962</issn><issn>1942-2970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpVUE1LAzEQXUSxtfoXJEcvC9kkm914EKT4BYVe9LzMppM2mmZrslso_nlTrEUvb2bePN5j5iQbF0qwnKmKnh57yUbZRYzvlMqSVvQ8G7GS8UowPs6-5sZgsH5J3JBAg9cYSNQB0e_ZviMru1zlwcYPssaF1RCQtOjRWG0hWIwkwjahs3sEvyA2Et3FPsdkrftE3yaagO6HpAeXBnC7aONldmbARbw61En29vjwOn3OZ_Onl-n9LN8wKfu85QXWSLGWiteSm0XBhYaypQAa6lZSvjCiEFBiSWtlFBrOBKZogaItaMUn2d2P72Zo0wkafR_ANZtg1xB2TQe2-b_xdtUsu20jCsmrSiWDm4NB6D4HjH2ztlGjc-CxG2JTlJIrxWrGkvT6b9Yx5Pfj_BsYy4HD</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Pyenson, Bruce S</creator><creator>Henschke, Claudia I</creator><creator>Yankelevitz, David F</creator><creator>Yip, Rowena</creator><creator>Dec, Ellynne</creator><general>Engage Healthcare Communications, LLC</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140801</creationdate><title>Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis</title><author>Pyenson, Bruce S ; Henschke, Claudia I ; Yankelevitz, David F ; Yip, Rowena ; Dec, Ellynne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-b31e8e0e8693863fd134ca5b0aaca8b603df414a5e5089f9ef324efec4e4b1073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Regulatory</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pyenson, Bruce S</creatorcontrib><creatorcontrib>Henschke, Claudia I</creatorcontrib><creatorcontrib>Yankelevitz, David F</creatorcontrib><creatorcontrib>Yip, Rowena</creatorcontrib><creatorcontrib>Dec, Ellynne</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American health &amp; drug benefits</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pyenson, Bruce S</au><au>Henschke, Claudia I</au><au>Yankelevitz, David F</au><au>Yip, Rowena</au><au>Dec, Ellynne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis</atitle><jtitle>American health &amp; drug benefits</jtitle><addtitle>Am Health Drug Benefits</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>7</volume><issue>5</issue><spage>272</spage><epage>282</epage><pages>272-282</pages><issn>1942-2962</issn><eissn>1942-2970</eissn><abstract>By a wide margin, lung cancer is the most significant cause of cancer death in the United States and worldwide. The incidence of lung cancer increases with age, and Medicare beneficiaries are often at increased risk. Because of its demonstrated effectiveness in reducing mortality, lung cancer screening with low-dose computed tomography (LDCT) imaging will be covered without cost-sharing starting January 1, 2015, by nongrandfathered commercial plans. Medicare is considering coverage for lung cancer screening. To estimate the cost and cost-effectiveness (ie, cost per life-year saved) of LDCT lung cancer screening of the Medicare population at high risk for lung cancer. Medicare costs, enrollment, and demographics were used for this study; they were derived from the 2012 Centers for Medicare &amp; Medicaid Services (CMS) beneficiary files and were forecast to 2014 based on CMS and US Census Bureau projections. Standard life and health actuarial techniques were used to calculate the cost and cost-effectiveness of lung cancer screening. The cost, incidence rates, mortality rates, and other parameters chosen by the authors were taken from actual Medicare data, and the modeled screenings are consistent with Medicare processes and procedures. Approximately 4.9 million high-risk Medicare beneficiaries would meet criteria for lung cancer screening in 2014. Without screening, Medicare patients newly diagnosed with lung cancer have an average life expectancy of approximately 3 years. Based on our analysis, the average annual cost of LDCT lung cancer screening in Medicare is estimated to be $241 per person screened. LDCT screening for lung cancer in Medicare beneficiaries aged 55 to 80 years with a history of ≥30 pack-years of smoking and who had smoked within 15 years is low cost, at approximately $1 per member per month. This assumes that 50% of these patients were screened. Such screening is also highly cost-effective, at &lt;$19,000 per life-year saved. If all eligible Medicare beneficiaries had been screened and treated consistently from age 55 years, approximately 358,134 additional individuals with current or past lung cancer would be alive in 2014. LDCT screening is a low-cost and cost-effective strategy that fits well within the standard Medicare benefit, including its claims payment and quality monitoring.</abstract><cop>United States</cop><pub>Engage Healthcare Communications, LLC</pub><pmid>25237423</pmid><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1942-2962
ispartof American health & drug benefits, 2014-08, Vol.7 (5), p.272-282
issn 1942-2962
1942-2970
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4163779
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Regulatory
title Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A08%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Offering%20lung%20cancer%20screening%20to%20high-risk%20medicare%20beneficiaries%20saves%20lives%20and%20is%20cost-effective:%20an%20actuarial%20analysis&rft.jtitle=American%20health%20&%20drug%20benefits&rft.au=Pyenson,%20Bruce%20S&rft.date=2014-08-01&rft.volume=7&rft.issue=5&rft.spage=272&rft.epage=282&rft.pages=272-282&rft.issn=1942-2962&rft.eissn=1942-2970&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1563992822%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1563992822&rft_id=info:pmid/25237423&rfr_iscdi=true